Dihydrodiosgenin protects against experimental acute pancreatitis and associated lung injury through mitochondrial protection and <scp>PI3Kγ/Akt</scp> inhibition

Abstract

These data provide in vitro and in vivo mechanistic evidence that the diosgenin analogue, Dydio could be potential treatment for AP. Further medicinal optimization of diosgenin and its analogue might be a useful strategy for identifying lead candidates for inflammatory diseases.